Physician profile
Simran Kaur
NPI 1336432194
$989.16
in general payments reported to CMS, 2019-2025
25 companies · $74.74 in 2025
The $74.74 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.88 · 2022: $192 · 2023: $211 · 2024: $483 · 2025: $74.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $171.73 | 2022-2023 | Dupixent |
| Genzyme Corporation | $94.04 | 2022-2023 | |
| Amgen INC. | $75.32 | 2024-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $72.95 | 2024 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $51.74 | 2024 | |
| Lilly USA, LLC | $50.86 | 2024 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $49.95 | 2021-2022 | |
| Optinose US, INC. | $47.46 | 2023 | |
| Abbvie INC. | $44.64 | 2024-2025 | |
| Novo Nordisk INC | $40.26 | 2024 | Rybelsus, Ozempic |
| Tandem Diabetes Care, INC. | $33.91 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $28.66 | 2024 | |
| Stryker Corporation | $25.03 | 2022 | |
| Verity Pharmaceuticals INC. | $24.79 | 2024 | Tlando |
| Insulet Corporation | $23.39 | 2024 | Omnipod |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $20.22 | 2024 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $18.63 | 2024 | Lokelma |
| Phadia US INC. | $17.09 | 2023 | Immunocap |
| Tolmar, INC. | $15.37 | 2024 | |
| Corcept Therapeutics | $14.71 | 2024 | Korlym |
| Amneal Pharmaceuticals LLC | $14.43 | 2024 | Unithroid |
| Astellas Pharma US INC | $14.10 | 2025 | Veozah |
| Currax Pharmaceuticals LLC | $13.71 | 2024 | Contrave |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2023 | Seglentis |
| Glaxosmithkline, LLC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.